Lee Ainslie Rocket Pharmaceuticals, Inc. Transaction History
Maverick Capital LTD
- $4.82 Billion
- Q3 2024
A detailed history of Lee Ainslie (Maverick Capital LTD) transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Maverick Capital LTD holds 4,118,672 shares of RCKT stock, worth $49.1 Million. This represents 1.58% of its overall portfolio holdings.
Number of Shares
4,118,672
Previous 3,928,312
4.85%
Holding current value
$49.1 Million
Previous $84.6 Million
10.06%
% of portfolio
1.58%
Previous 1.67%
Shares
13 transactions
Others Institutions Holding RCKT
# of Institutions
209Shares Held
93.2MCall Options Held
319KPut Options Held
70.3K-
Rtw Investments, LP New York, NY17.7MShares$211 Million5.21% of portfolio
-
Wellington Management Group LLP Boston, MA11.2MShares$134 Million0.04% of portfolio
-
Black Rock Inc. New York, NY6.19MShares$73.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.54MShares$66 Million0.0% of portfolio
-
Westfield Capital Management CO LP Boston, MA4.49MShares$53.6 Million0.39% of portfolio
About ROCKET PHARMACEUTICALS, INC.
- Ticker RCKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 75,683,696
- Market Cap $902M
- Description
- Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...